154 related articles for article (PubMed ID: 1366927)
21. Recombinant acellular pertussis vaccine--from the laboratory to the clinic: improving the quality of the immune response.
Rappuoli R; Pizza M; Covacci A; Bartoloni A; Nencioni L; Podda A; De Magistris MT
FEMS Microbiol Immunol; 1992 Oct; 5(4):161-70. PubMed ID: 1384602
[TBL] [Abstract][Full Text] [Related]
22. Rational design of vaccines.
Rappuoli R
Nat Med; 1997 Apr; 3(4):374-6. PubMed ID: 9095163
[No Abstract] [Full Text] [Related]
23. Role of pertactin in pertussis vaccines: the jury is still out.
Desauziers E; Danve B; Decker MD; Veitch K
J Infect Dis; 2004 Apr; 189(7):1332-3; author reply 1333-5. PubMed ID: 15031804
[No Abstract] [Full Text] [Related]
24. Immunoprophylaxis in pertussis.
Deb M
J Commun Dis; 1984 Mar; 16(1):54-60. PubMed ID: 12055788
[TBL] [Abstract][Full Text] [Related]
25. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
Dorji D; Mooi F; Yantorno O; Deora R; Graham RM; Mukkur TK
Med Microbiol Immunol; 2018 Feb; 207(1):3-26. PubMed ID: 29164393
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of acellular pertussis vaccines].
Wirsing von König CH; Finger H
Immun Infekt; 1995 Aug; 23(4):125-9. PubMed ID: 7558115
[TBL] [Abstract][Full Text] [Related]
27. Comparison of recombinant and native pertactin of Bordetella pertussis.
Xu Y; Zhang S; Bolgiano B; Tan Y; Asokanathan C; Zhang H; Xing D; Wang J
Vaccine; 2011 Feb; 29(10):1974-80. PubMed ID: 21216309
[TBL] [Abstract][Full Text] [Related]
28. The role of B. pertussis vaccine antigen gene variants in pertussis resurgence and possible consequences for vaccine development.
Preston A
Hum Vaccin Immunother; 2016 May; 12(5):1274-6. PubMed ID: 26889694
[TBL] [Abstract][Full Text] [Related]
29. Rapid and accurate typing of Bordetella pertussis targeting genes encoding acellular vaccine antigens using real time PCR and High Resolution Melt analysis.
Chan WF; Maharjan RP; Reeves PR; Sintchenko V; Gilbert GL; Lan R
J Microbiol Methods; 2009 Jun; 77(3):326-9. PubMed ID: 19341769
[TBL] [Abstract][Full Text] [Related]
30. Pertussis vaccines: present status.
Christodoulides M
Adv Biotechnol Processes; 1990; 13():169-99. PubMed ID: 2185783
[TBL] [Abstract][Full Text] [Related]
31. Bordetella pertussis pertactin knock-out strains reveal immunomodulatory properties of this virulence factor.
Hovingh ES; Mariman R; Solans L; Hijdra D; Hamstra HJ; Jongerius I; van Gent M; Mooi F; Locht C; Pinelli E
Emerg Microbes Infect; 2018 Mar; 7(1):39. PubMed ID: 29559630
[TBL] [Abstract][Full Text] [Related]
32. Genetic approaches to a vaccine for pertussis.
Nencioni L; Pizza M; Volpini G; Podda A; Rappuoli R
Adv Exp Med Biol; 1991; 303():119-27. PubMed ID: 1805560
[No Abstract] [Full Text] [Related]
33. Surfaceome analysis of Australian epidemic Bordetella pertussis reveals potential vaccine antigens.
Luu LDW; Octavia S; Aitken C; Zhong L; Raftery MJ; Sintchenko V; Lan R
Vaccine; 2020 Jan; 38(3):539-548. PubMed ID: 31703933
[TBL] [Abstract][Full Text] [Related]
34. Pertussis infection and vaccination induces Th1 cells.
Brady MT; Mahon BP; Mills KH
Immunol Today; 1998 Nov; 19(11):534. PubMed ID: 9818551
[No Abstract] [Full Text] [Related]
35. Haemagglutination induced by Bordetella pertussis filamentous haemagglutinin adhesin (FHA) is inhibited by antibodies produced against FHA(430-873) fragment expressed in Lactobacillus casei.
Colombi D; Oliveira ML; Campos IB; Monedero V; Pérez-Martinez G; Ho PL
Curr Microbiol; 2006 Dec; 53(6):462-6. PubMed ID: 17106803
[TBL] [Abstract][Full Text] [Related]
36. A recombinant iron transport protein from Bordetella pertussis confers protection against Bordetella parapertussis.
Alvarez Hayes J; Oviedo JM; Valdez H; Laborde JM; Maschi F; Ayala M; Shah R; Fernandez Lahore M; Rodriguez ME
Microbiol Immunol; 2017 Oct; 61(10):407-415. PubMed ID: 28857261
[TBL] [Abstract][Full Text] [Related]
37. Bordetella pertussis from functional genomics to intranasal vaccination.
Locht C; Antoine R; Raze D; Mielcarek N; Hot D; Lemoine Y; Mascart F
Int J Med Microbiol; 2004 Apr; 293(7-8):583-8. PubMed ID: 15149035
[TBL] [Abstract][Full Text] [Related]
38. [Engineering of attenuated Bordetella pertussis bacteria producing immunogenic non-toxic form of pertussis toxin].
Siniashina LN; Nechaeva EV; Amelina IP; Karataev GI
Zh Mikrobiol Epidemiol Immunobiol; 2009; (6):89-94. PubMed ID: 20095432
[TBL] [Abstract][Full Text] [Related]
39. Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine.
Hegerle N; Dore G; Guiso N
Vaccine; 2014 Nov; 32(49):6597-600. PubMed ID: 25312274
[TBL] [Abstract][Full Text] [Related]
40. Genome characteristics of
Ben Fraj I; Bouchez V; Smaoui H; Kechrid A; Brisse S
J Med Microbiol; 2019 Sep; 68(9):1320-1323. PubMed ID: 31329091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
